Novel pyranyl cyanoguanidine compounds act as potassium channel activators with anti-ischaemic efficacy and minimal vasodilatory activity in rat models, suggesting potential utility in transplant surgery.
No takes yet. Share an insight, caveat, or question.
Should not yet change transplant practice; leaves open further development of selective anti-ischaemic agents.
A 1992 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: